The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong

@article{Chan2001TheCO,
  title={The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong},
  author={David C.M. Chan and Philip Jacobs and Winnie Yeo and Maria Paola Lai and Clarke Hazlett and Tony Shu-Kam Mok and Thomas Wai Tong Leung and Wan Yee Joseph Lau and Philip James Johnson},
  journal={PharmacoEconomics},
  year={2001},
  volume={19},
  pages={947-953}
}
Background: Hepatocellular carcinoma (HCC)is endemic in parts of Asia and Africa and most patients are not suitable for treatment with a curative approach. Little is known about the cost of palliative care for HCC. Objective: To determine: (i) patient-specific costs of palliative care of HCC; and (ii) individual factors that drive patient-specific costs and to develop a model of cost per case under alternative circumstances. Methods: 204 patients with inoperable HCC were prospectively tracked… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

1995/6 technical portion of the diagnostic imaging common procedure/examination lost (cpel)

  • Alberta Health
  • 1995
Highly Influential
3 Excerpts

Cancer Registry. Cancer incidence and mortality in Hong Kong 1993-1994

  • Hong Kong
  • Hong Kong: Hospital Authority,
  • 1998
2 Excerpts

Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh classAcirrhosis.Am JMed

  • Sarasin FPGE, HadengueA
  • 1996
2 Excerpts

Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

  • Groupe d’Etude et de
  • N Engl J Med
  • 1995
1 Excerpt

Similar Papers

Loading similar papers…